Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide vs Biphasic Insulin Aspart in Type 2 Diabetes
NCT00082407Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2003
- Primary completion
- Jul 2008
- Modality
- Peptides
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of exenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in Glycosylated Hemoglobin at 52 weeks. Started Nov 2003; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00082407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082407.